Moyer J D, Karle J M, Malinowski N, Marquez V E, Salam M A, Malspeis L, Cysyk R L
Mol Pharmacol. 1985 Nov;28(5):454-60.
Uridine kinase can play a crucial role in the provision of pyrimidine nucleotides for cellular nucleic acid synthesis, particularly when de novo synthesis is inhibited by chemotherapeutic agents. Therefore, uridine kinase is an attractive target for drug development. We examined a series of 29 analogs of uridine, most with modifications at the 5'-position, as inhibitors of uridine kinase in vitro and of uridine salvage by intact L1210 cells. Substitution at the 5'-position resulted in decreased efficacy as inhibitors of uridine kinase, particularly if the substituent was large. None of the analogs with 5'-position modifications effectively inhibited salvage of uridine by intact L1210 cells. Four carbocyclic pyrimidine nucleoside analogs (one series) were all effective competitive inhibitors of uridine kinase and of uridine salvage by intact L1210 cells. Cyclopentenyl uracil 19 shows promise for further development as it inhibits uridine salvage at nontoxic concentrations.
尿苷激酶在为细胞核酸合成提供嘧啶核苷酸方面可发挥关键作用,尤其是在从头合成受到化疗药物抑制时。因此,尿苷激酶是药物开发的一个有吸引力的靶点。我们研究了一系列29种尿苷类似物,其中大多数在5'-位有修饰,作为尿苷激酶的体外抑制剂以及完整L1210细胞对尿苷补救途径的抑制剂。在5'-位进行取代导致作为尿苷激酶抑制剂的效力降低,尤其是当取代基很大时。没有一种在5'-位有修饰的类似物能有效抑制完整L1210细胞对尿苷的补救途径。四种碳环嘧啶核苷类似物(一个系列)都是尿苷激酶的有效竞争性抑制剂,也是完整L1210细胞对尿苷补救途径的有效抑制剂。环戊烯基尿嘧啶19在无毒浓度下可抑制尿苷补救途径,显示出进一步开发的前景。